WO2023195955A1 - A film coated tablet comprising selexi̇pag and its preparation process - Google Patents

A film coated tablet comprising selexi̇pag and its preparation process Download PDF

Info

Publication number
WO2023195955A1
WO2023195955A1 PCT/TR2023/050304 TR2023050304W WO2023195955A1 WO 2023195955 A1 WO2023195955 A1 WO 2023195955A1 TR 2023050304 W TR2023050304 W TR 2023050304W WO 2023195955 A1 WO2023195955 A1 WO 2023195955A1
Authority
WO
WIPO (PCT)
Prior art keywords
film coated
coated tablet
selexipag
cellulose
tablet according
Prior art date
Application number
PCT/TR2023/050304
Other languages
French (fr)
Inventor
Fatih Sunel
Fadime Bilgehan ATAK
Nur PEHLIVAN AKALIN
Guldeniz TUNC
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2023195955A1 publication Critical patent/WO2023195955A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • the present invention relates to a film coated tablet comprising selexipag or crystalline polymorph thereof and at least one pharmaceutically acceptable excipient, wherein tablet comprising at least one filler and the tablet is free of mannitol. Furthermore, the tablet is obtained using wet granulation with geometric dilution method.
  • Selexipag is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary arterial hypertension (PAH).
  • Selexipag also known as 2-(4-((5,6- diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide can be represented by the following chemical structure according to Formula I:
  • each round film-coated tablet for oral administration contains 200, 400, 600, 800, 1000, 1200, 1400, or 1600 mcg of Selexipag.
  • the Uptravi® film-coated tablet is a standard immediate-release tablet that contains D-mannitol, corn starch, low substituted hydroxypropylcellulose, hydroxypropylcellulose, and magnesium stearate.
  • the tablets are film coated with a coating material containing hypromellose, propylene glycol, titanium dioxide, carnauba wax along with mixtures of iron oxide red, iron oxide yellow or iron oxide black.
  • Selexipag is considered to be a BCS (Biopharmaceutics Classification System) Class II drug, i.e. having high permeability and low solubility.
  • BCS Biopharmaceutics Classification System
  • EP3481807 discloses novel crystalline forms of selexipag and its process for the preparation thereof.
  • WO 2017/029594 describes the preparation of amorphous selexipag by dissolving the drug in a suitable solvent, e.g. acetone, and removing the solvent by, e.g., evaporation, spray-drying or freeze- drying.
  • EP3705115 discloses a solid unit dosage form for oral administration (tablet or granules) containing non-crystalline selexipag in a polymeric matrix and mannitol.
  • the solid dispersion is prepared by hot-melt extrusion, whereby the milled extrudate is subsequently subjected to a drygranulation process.
  • the main object of the present invention is to provide a film coated tablet comprises or crystalline polymorph thereof with having the desired level of dissolution rate and high stability and excellent physicochemical properties, such as flowability, compressibility, homogeneity, and content uniformity which overcomes the above-described problems in the prior art and have additive advantages over them.
  • Another object of the present invention is to provide a process for preparing a film coated tablet composition comprising selexipag or crystalline polymorph thereof.
  • the process is a simple, rapid, cost effective, time-saving, and industrially convenient method.
  • the process is wet granulation with geometric dilution method.
  • a film coated tablet comprises selexipag or crystalline polymorph thereof and at least one filler wherein the amount of filler is between 70.0% and 95.0% by weight of the total tablet and the tablet is free of mannitol.
  • the use of the filler at the described amount helps to provide the uniformity of the content and so the desired dissolution profile.
  • Suitable fillers are selected from the group comprising corn starch, microcrystalline cellulose, lactose monohydrate, cellulose, cellulose acetate, compressible sugar, ethylcellulose, lactitol, lactose, magnesium oxide, maltodextrin, maltose, sorbitol, sucrose, talc or mixtures thereof.
  • fillers are lactose monohydrate and corn starch.
  • lactose monohydrate and corn starch together help to provide both the desired stability and excellent physicochemical properties. It is advantageous to use lactose monohydrate instead of mannitol in order to ensure proper homogeneity, prevent particle size differences and provide the appropriate mixture.
  • the amount of filler is between 78.0% and 90.0% by weight of the total tablet.
  • the amount of corn starch is between 25.0% and 45.0%, between 30.0% and 40.0% by weight of the total tablet and the amount of lactose monohydrate is between 45.0% and 58.0%, between 48.0% and 56.0% by weight of the total tablet.
  • the amount of selexipag or crystalline polymorph thereof is between 0.05% and 5.0%, preferably between 0.05% and 2.0% by weight of the total tablet.
  • selexipag is present in the form of amorph or form P or form 3 or form 1 or mixtures thereof.
  • selexipag is present in the form of amorph.
  • selexipag is present in the form of form P. It provides a tablet with high yields and purity. According to one embodiment of this invention, selexipag is present in the form of form 3.
  • the film coated tablet further comprises at least one pharmaceutically acceptable excipient selected from the group comprising disintegrants, binders, lubricants or mixtures thereof.
  • Suitable disintegrants are selected from the group comprising low-substituted hydroxypropyl cellulose, croscarmellose sodium, crospovidone, carboxymethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, hydroxymethyl starch or mixtures thereof.
  • the disintegrant is low-substituted hydroxypropyl cellulose.
  • low-substituted hydroxypropyl cellulose has proven to offer substantial advantages as disintegrant because of its ability to turn low-soluble selexipag into fast-dissolving stable tablets. Also, its use in the specified range provided the desired dissolution profile.
  • the amount of low-substituted hydroxypropyl cellulose is between 2.0% and 10.0% by weight of the total tablet.
  • Suitable binders are selected from the group comprising hydroxypropyl methyl cellulose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, polyethylene glycol, starch, pregelatinized starch, sodium alginate, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, polymethacrylates, methacrylate polymers, polysaccharides, carbomer, poloxamer, polydextrose, polyethylene oxide or mixtures thereof.
  • the binder is hydroxypropyl methyl cellulose.
  • HPMC hydroxypropyl methyl cellulose.
  • the amount of binder is between 1.0% and 8.0%, between 2.0% and 6.0% by weight of the total tablet.
  • Suitable lubricants are selected from the group comprising magnesium stearate, calcium stearate, sodium stearyl fumarate, potassium stearate, stearic acid, sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols or mixtures thereof.
  • the lubricant is magnesium stearate. According to one embodiment of this invention, the amount of lubricant is between 0.5% and 3.5% by weight of the total tablet.
  • the film coated tablet further comprises at least one coloring agent.
  • Suitable coloring agents are selected from the group comprising indigo carmin aluminum lake, ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof. Coloring agent contributes positively to the shelf life of the product and so the desired stability. Due to their nature, coloring agents show antioxidant properties and often prevent the active substance from being oxidized. It also provides photostability by preventing contact with light.
  • FD&C Drug & Cosmetic
  • the film coated tablet comprises;
  • the film coated tablet comprises;
  • Magnesium stearate Magnesium stearate.
  • the film coated tablet comprises;
  • Magnesium stearate Magnesium stearate.
  • the film coated tablet is obtained by wet granulation using solvent.
  • Suitable solvents are selected from the group comprising pure water, dichloromethane, 0.1N HCI, methanol, ethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, polyethylene glycol, glycerine, cyclomethicone, glycerine triacetate, diethylene glycol monoethyl ether or mixtures thereof.
  • the solvent is water or dichloromethane or methanol or ethanol or isopropyl alcohol or mixtures thereof.
  • a process for preparing a film coated tablet comprising selexipag or crystalline polymorph thereof comprises the following steps: a) Dissolving a binder in solvent and adjusting pH at the solution in the range of 5-8, b) Mixing selexipag or crystalline polymorph thereof and a half of a disintegrant, and then adding another half of a disintegrant and mixing again, c) Adding % of a filler and mixing, then adding the remaining part of the filler and mixing again, d) Adding a half of else a filler and mixing, and then adding another half of the filler and mixing, e) Granulating the dry mixture at step (d) with the solution step (a) and obtained wet granules.
  • Selexipag or crystalline polymorph thereof presents in low amount in the tablet. Thanks to using wet granulation with geometric dilution method, at the present invention, the film coated tablet which has a low amount of selexipag or crystalline polymorph thereof has been developed with excellent physicochemical properties. Also, this provides the desired stability and dissolution profile of the tablet.
  • This geometric dilution method provides the homogeneity and content uniformity of the active substance used in low amounts and the desired dissolution profile.
  • wet granulation with geometric dilution method is preferred in terms of pharmacotechnical properties, such as flowability, compressibility and content uniformity of selexipag.
  • suitable solvent also provides the desired stability.
  • a process for preparing a film coated tablet comprising selexipag or crystalline polymorph thereof comprises the following steps: a) Dissolving a binder in solvent and adjusting pH at the solution in the range of 5-8, b) Mixing selexipag or crystalline polymorph thereof and a half of a disintegrant, and then adding another half of a disintegrant and mixing again, c) Adding % of a filler and mixing, then adding the remaining part of the filler and mixing again, d) Adding a half of else a filler and mixing, sieving into 0.8 mm and then adding another half of the filler and mixing.
  • a process for preparing a film coated tablet comprising selexipag or crystalline polymorph thereof comprises the following steps: a) Dissolving hydroxypropyl methyl Cellulose in solvent and adjusting pH at the solution in the range of 5-8, b) Mixing selexipag or crystalline polymorph thereof and a half of low substituted hydroxypropyl cellulose, and then adding another half of low substituted hydroxypropyl cellulose and mixing again, c) Adding % of corn starch and mixing, then adding the remaining part of corn starch and mixing again, d) Adding a half of lactose monohydrate and mixing, sieving into 0.8 mm, and then adding another half of lactose monohydrate and mixing, e) Granulating the dry mixture at step (d) with the solution step (a) and obtained wet granules, f) Drying the wet granules and then sieving, g) Adding magnesium stearate and then mixing,
  • a process for example 1 or 2 a) Dissolving hydroxypropyl methyl Cellulose in solvent and adjusting pH at the solution in the range of 5-8, b) Mixing selexipag or crystalline polymorph thereof and a half of low substituted hydroxypropyl cellulose, and then adding another half of low substituted hydroxypropyl cellulose and mixing again, c) Adding % of corn starch and mixing, then adding the remaining part of corn starch and mixing again, d) Adding a half of lactose monohydrate and mixing, sieving into 0.8 mm, and then adding another half of lactose monohydrate and mixing, e) Granulating the dry mixture at step (d) with the solution step (a) and obtained wet granules, f) Drying the wet granules and then sieving, g) Adding magnesium stearate and then mixing, h) Compressing the mixture into tablets, i) Coating the tablets.
  • a process for example 3 a) Dissolving hydroxypropyl methyl Cellulose in solvent and adjusting pH at the solution in the range of 5-8, b) Mixing selexipag or crystalline polymorph thereof and a half of low substituted hydroxypropyl cellulose, and then adding another half of low substituted hydroxypropyl cellulose and mixing again, c) Adding % of corn starch and mixing, then adding the remaining part of corn starch and mixing again, d) Adding a half of lactose monohydrate and mixing, sieving into 0.8 mm, and then adding another half of lactose monohydrate and mixing, e) Granulating the dry mixture at step (d) with the solution step (a) and obtained wet granules, f) Drying the wet granules and then sieving, g) Adding coloring agent and mixing, h) Adding magnesium stearate and then mixing, i) Compressing the mixture into tablets, j) Coating the tablets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a film coated tablet comprising selexipag or crystalline polymorph thereof and at least one pharmaceutically acceptable excipient, wherein tablet comprising at least one filler and the tablet is free of mannitol. Furthermore, the tablet is obtained using wet granulation with geometric dilution method.

Description

A FILM COATED TABLET COMPRISING SELEXiPAG AND ITS PREPARATION PROCESS
Field of the Invention
The present invention relates to a film coated tablet comprising selexipag or crystalline polymorph thereof and at least one pharmaceutically acceptable excipient, wherein tablet comprising at least one filler and the tablet is free of mannitol. Furthermore, the tablet is obtained using wet granulation with geometric dilution method.
Background of the Invention
Selexipag is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary arterial hypertension (PAH). Selexipag also known as 2-(4-((5,6- diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide can be represented by the following chemical structure according to Formula I:
Figure imgf000002_0001
Formula I: Selexipag
Depending on the dose strength, each round film-coated tablet for oral administration contains 200, 400, 600, 800, 1000, 1200, 1400, or 1600 mcg of Selexipag. The Uptravi® film-coated tablet is a standard immediate-release tablet that contains D-mannitol, corn starch, low substituted hydroxypropylcellulose, hydroxypropylcellulose, and magnesium stearate. The tablets are film coated with a coating material containing hypromellose, propylene glycol, titanium dioxide, carnauba wax along with mixtures of iron oxide red, iron oxide yellow or iron oxide black.
Selexipag is considered to be a BCS (Biopharmaceutics Classification System) Class II drug, i.e. having high permeability and low solubility.
EP3481807 (Al) discloses novel crystalline forms of selexipag and its process for the preparation thereof. WO 2017/029594 describes the preparation of amorphous selexipag by dissolving the drug in a suitable solvent, e.g. acetone, and removing the solvent by, e.g., evaporation, spray-drying or freeze- drying.
EP3705115 (Al) discloses a solid unit dosage form for oral administration (tablet or granules) containing non-crystalline selexipag in a polymeric matrix and mannitol. The solid dispersion is prepared by hot-melt extrusion, whereby the milled extrudate is subsequently subjected to a drygranulation process.
In prior art, there are also several patents which disclose selexipag in oral pharmaceutical dosage forms. However, despite the dissolution problem of selexipag, an effective formulation and method has not been disclosed.
There still remains a need in the art to provide an improved a film coated tablet comprising selexipag or crystalline polymorph thereof having high solubility, excellent physicochemical properties and accordingly a high bioavailability and a long-term stability.
Detailed Description of the Invention
The main object of the present invention is to provide a film coated tablet comprises or crystalline polymorph thereof with having the desired level of dissolution rate and high stability and excellent physicochemical properties, such as flowability, compressibility, homogeneity, and content uniformity which overcomes the above-described problems in the prior art and have additive advantages over them.
Another object of the present invention is to provide a process for preparing a film coated tablet composition comprising selexipag or crystalline polymorph thereof. The process is a simple, rapid, cost effective, time-saving, and industrially convenient method. Preferably, the process is wet granulation with geometric dilution method.
Like the other poorly soluble in water molecules, low solubility of selexipag results in low dissolution. Also, selexipag or crystalline polymorph thereof is used small proportion that can lead to considerable problems during the manufacture of the composition with regard to the uniformity of the content of active agent in the individual composition units. Because of problems uniformity of the content, the active substance may interact with several excipients. It reflects that content uniformity make an important role in the dissolution of the drug. According to one embodiment of this invention, a film coated tablet comprises selexipag or crystalline polymorph thereof and at least one filler wherein the amount of filler is between 70.0% and 95.0% by weight of the total tablet and the tablet is free of mannitol.
According to one embodiment of this invention, the use of the filler at the described amount helps to provide the uniformity of the content and so the desired dissolution profile.
The suitable filler used instead of mannitol gives better results in terms of powder flow and compaction properties.
Suitable fillers are selected from the group comprising corn starch, microcrystalline cellulose, lactose monohydrate, cellulose, cellulose acetate, compressible sugar, ethylcellulose, lactitol, lactose, magnesium oxide, maltodextrin, maltose, sorbitol, sucrose, talc or mixtures thereof.
According to one embodiment of the present invention, fillers are lactose monohydrate and corn starch. Using lactose monohydrate and corn starch together help to provide both the desired stability and excellent physicochemical properties. It is advantageous to use lactose monohydrate instead of mannitol in order to ensure proper homogeneity, prevent particle size differences and provide the appropriate mixture.
According to one embodiment of this invention, the amount of filler is between 78.0% and 90.0% by weight of the total tablet.
According to one embodiment of this invention, the amount of corn starch is between 25.0% and 45.0%, between 30.0% and 40.0% by weight of the total tablet and the amount of lactose monohydrate is between 45.0% and 58.0%, between 48.0% and 56.0% by weight of the total tablet.
According to one embodiment of this invention, the amount of selexipag or crystalline polymorph thereof is between 0.05% and 5.0%, preferably between 0.05% and 2.0% by weight of the total tablet.
According to one embodiment of this invention, selexipag is present in the form of amorph or form P or form 3 or form 1 or mixtures thereof.
According to one embodiment of this invention, selexipag is present in the form of amorph.
According to one embodiment of this invention, selexipag is present in the form of form P. It provides a tablet with high yields and purity. According to one embodiment of this invention, selexipag is present in the form of form 3.
According to one embodiment of the present invention, the film coated tablet further comprises at least one pharmaceutically acceptable excipient selected from the group comprising disintegrants, binders, lubricants or mixtures thereof.
Suitable disintegrants are selected from the group comprising low-substituted hydroxypropyl cellulose, croscarmellose sodium, crospovidone, carboxymethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, hydroxymethyl starch or mixtures thereof.
According to one embodiment of this invention, the disintegrant is low-substituted hydroxypropyl cellulose. In this invention, we found that low-substituted hydroxypropyl cellulose has proven to offer substantial advantages as disintegrant because of its ability to turn low-soluble selexipag into fast-dissolving stable tablets. Also, its use in the specified range provided the desired dissolution profile.
According to one embodiment of this invention, the amount of low-substituted hydroxypropyl cellulose is between 2.0% and 10.0% by weight of the total tablet.
Suitable binders are selected from the group comprising hydroxypropyl methyl cellulose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, polyethylene glycol, starch, pregelatinized starch, sodium alginate, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, polymethacrylates, methacrylate polymers, polysaccharides, carbomer, poloxamer, polydextrose, polyethylene oxide or mixtures thereof.
According to one embodiment of the present invention, the binder is hydroxypropyl methyl cellulose. The use of HPMC while preparing the solution in which selexipag dissolves provided the pH range required for the dissolution of selexipag. This pH range is between 5 and 8.
According to one embodiment of this invention, the amount of binder is between 1.0% and 8.0%, between 2.0% and 6.0% by weight of the total tablet.
Suitable lubricants are selected from the group comprising magnesium stearate, calcium stearate, sodium stearyl fumarate, potassium stearate, stearic acid, sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols or mixtures thereof.
According to one embodiment of the present invention, the lubricant is magnesium stearate. According to one embodiment of this invention, the amount of lubricant is between 0.5% and 3.5% by weight of the total tablet.
According to one embodiment of the present invention, the film coated tablet further comprises at least one coloring agent.
Suitable coloring agents are selected from the group comprising indigo carmin aluminum lake, ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof. Coloring agent contributes positively to the shelf life of the product and so the desired stability. Due to their nature, coloring agents show antioxidant properties and often prevent the active substance from being oxidized. It also provides photostability by preventing contact with light.
According to one embodiment of this invention, the film coated tablet comprises;
Crystalline form-P or 1 or 3 or amorph of selexipag
Lactose monohydrate
Corn starch
Coloring agent
According to one embodiment of this invention, the film coated tablet comprises;
Crystalline form-P or 1 or 3 or amorph of selexipag and
Hydroxypropyl methyl Cellulose E3 LV
Lactose monohydrate
Corn starch
Low-substituted hydroxypropyl cellulose
Magnesium stearate.
According to one embodiment of this invention, the film coated tablet comprises;
Crystalline form-P or 1 or 3 or amorph of selexipag
Hydroxypropyl methyl Cellulose E3 LV
Lactose monohydrate
Corn starch
Low-substituted hydroxypropyl cellulose
Magnesium stearate.
Coloring agent. According to one embodiment of this invention, the film coated tablet is obtained by wet granulation using solvent.
Suitable solvents are selected from the group comprising pure water, dichloromethane, 0.1N HCI, methanol, ethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, polyethylene glycol, glycerine, cyclomethicone, glycerine triacetate, diethylene glycol monoethyl ether or mixtures thereof. Preferably, the solvent is water or dichloromethane or methanol or ethanol or isopropyl alcohol or mixtures thereof.
According to one embodiment of this invention, a process for preparing a film coated tablet comprising selexipag or crystalline polymorph thereof comprises the following steps: a) Dissolving a binder in solvent and adjusting pH at the solution in the range of 5-8, b) Mixing selexipag or crystalline polymorph thereof and a half of a disintegrant, and then adding another half of a disintegrant and mixing again, c) Adding % of a filler and mixing, then adding the remaining part of the filler and mixing again, d) Adding a half of else a filler and mixing, and then adding another half of the filler and mixing, e) Granulating the dry mixture at step (d) with the solution step (a) and obtained wet granules.
Selexipag or crystalline polymorph thereof presents in low amount in the tablet. Thanks to using wet granulation with geometric dilution method, at the present invention, the film coated tablet which has a low amount of selexipag or crystalline polymorph thereof has been developed with excellent physicochemical properties. Also, this provides the desired stability and dissolution profile of the tablet.
This geometric dilution method provides the homogeneity and content uniformity of the active substance used in low amounts and the desired dissolution profile.
In this invention, to eliminate this problem, wet granulation with geometric dilution method is preferred in terms of pharmacotechnical properties, such as flowability, compressibility and content uniformity of selexipag. Using suitable solvent also provides the desired stability.
According to one embodiment of this invention, a process for preparing a film coated tablet comprising selexipag or crystalline polymorph thereof comprises the following steps: a) Dissolving a binder in solvent and adjusting pH at the solution in the range of 5-8, b) Mixing selexipag or crystalline polymorph thereof and a half of a disintegrant, and then adding another half of a disintegrant and mixing again, c) Adding % of a filler and mixing, then adding the remaining part of the filler and mixing again, d) Adding a half of else a filler and mixing, sieving into 0.8 mm and then adding another half of the filler and mixing. e) Granulating the dry mixture at step (d) with the solution step (a) and obtained wet granules, f) Drying the wet granules in an oven at 50 °C to the appropriate humidity value and then sieving, g) Adding at least one lubricant and then mixing, h) Compressing the mixture into tablets, i) Coating the tablets.
According to one embodiment of this invention, a process for preparing a film coated tablet comprising selexipag or crystalline polymorph thereof comprises the following steps: a) Dissolving hydroxypropyl methyl Cellulose in solvent and adjusting pH at the solution in the range of 5-8, b) Mixing selexipag or crystalline polymorph thereof and a half of low substituted hydroxypropyl cellulose, and then adding another half of low substituted hydroxypropyl cellulose and mixing again, c) Adding % of corn starch and mixing, then adding the remaining part of corn starch and mixing again, d) Adding a half of lactose monohydrate and mixing, sieving into 0.8 mm, and then adding another half of lactose monohydrate and mixing, e) Granulating the dry mixture at step (d) with the solution step (a) and obtained wet granules, f) Drying the wet granules and then sieving, g) Adding magnesium stearate and then mixing, h) Compressing the mixture into tablets, i) Coating the tablets. Example 1:
Figure imgf000009_0001
Example 2:
Figure imgf000009_0002
A process for example 1 or 2; a) Dissolving hydroxypropyl methyl Cellulose in solvent and adjusting pH at the solution in the range of 5-8, b) Mixing selexipag or crystalline polymorph thereof and a half of low substituted hydroxypropyl cellulose, and then adding another half of low substituted hydroxypropyl cellulose and mixing again, c) Adding % of corn starch and mixing, then adding the remaining part of corn starch and mixing again, d) Adding a half of lactose monohydrate and mixing, sieving into 0.8 mm, and then adding another half of lactose monohydrate and mixing, e) Granulating the dry mixture at step (d) with the solution step (a) and obtained wet granules, f) Drying the wet granules and then sieving, g) Adding magnesium stearate and then mixing, h) Compressing the mixture into tablets, i) Coating the tablets.
Example 3:
Figure imgf000010_0001
A process for example 3; a) Dissolving hydroxypropyl methyl Cellulose in solvent and adjusting pH at the solution in the range of 5-8, b) Mixing selexipag or crystalline polymorph thereof and a half of low substituted hydroxypropyl cellulose, and then adding another half of low substituted hydroxypropyl cellulose and mixing again, c) Adding % of corn starch and mixing, then adding the remaining part of corn starch and mixing again, d) Adding a half of lactose monohydrate and mixing, sieving into 0.8 mm, and then adding another half of lactose monohydrate and mixing, e) Granulating the dry mixture at step (d) with the solution step (a) and obtained wet granules, f) Drying the wet granules and then sieving, g) Adding coloring agent and mixing, h) Adding magnesium stearate and then mixing, i) Compressing the mixture into tablets, j) Coating the tablets.

Claims

1) A film coated tablet comprising selexipag or crystalline polymorph thereof and at least one filler wherein the amount of filler is between 70.0% and 95.0% by weight of the total tablet and the tablet is free of mannitol.
2) The film coated tablet according to claim 1, wherein fillers are selected from the group comprising corn starch, microcrystalline cellulose, lactose monohydrate, cellulose, cellulose acetate, compressible sugar, ethylcellulose, lactitol, lactose, magnesium oxide, maltodextrin, maltose, sorbitol, sucrose, talc or mixtures thereof.
3) The film coated tablet according to claim 1, wherein fillers are lactose monohydrate and corn starch.
4) The film coated tablet according to claim 3, wherein the amount of corn starch is between 25.0% and 45.0%, between 30.0% and 40.0% by weight of the total tablet and the amount of lactose monohydrate is between 45.0% and 58.0%, between 48.0% and 56.0% by weight of the total tablet.
5) The film coated tablet according to claim 1, wherein selexipag is present in the form of amorph or form P or form 3 or form 1 or mixtures thereof.
6) The film coated tablet according to claim 1, wherein the film coated tablet further comprising at least one pharmaceutically acceptable excipient selected from the group comprising disintegrants, binders, lubricants or mixtures thereof.
7) The film coated tablet according to claim 6, wherein disintegrants are selected from the group comprising low-substituted hydroxypropyl cellulose, croscarmellose sodium, crospovidone, carboxymethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, hydroxymethyl starch or mixtures thereof.
8) The film coated tablet according to claim 7, wherein the disintegrant is low-substituted hydroxypropyl cellulose.
9) The film coated tablet according to claim 6, wherein binders are selected from the group comprising hydroxypropyl methyl cellulose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, polyethylene glycol, starch, pregelatinized starch, sodium alginate, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, polymethacrylates, methacrylate polymers, polysaccharides, carbomer, poloxamer, polydextrose, polyethylene oxide or mixtures thereof. ) The film coated tablet according to claim 9, wherein the binder is hydroxypropyl methyl cellulose. ) The film coated tablet according to any preceding claim, wherein the film coated tablet further comprising at least one coloring agent. ) The film coated tablet according to claim 11, wherein the film coated tablet comprising;
Crystalline form-P or 1 or 3 or amorph of selexipag
Lactose monohydrate
Corn starch
Coloring agent ) The film coated tablet according to claim 6, wherein the film coated tablet comprising;
Crystalline form-P or 1 or 3 or amorph of selexipag and
Hydroxypropyl methyl Cellulose E3 LV
Lactose monohydrate
Corn starch
Low-substituted hydroxypropyl cellulose
Magnesium stearate. ) The film coated tablet according to claim 1, wherein the film coated tablet is obtained by wet granulation with geometric dilution method. ) A process for preparing a film coated tablet comprising selexipag or crystalline polymorph thereof comprising the following steps: a) Dissolving a binder in solvent and adjusting pH at the solution in the range of 5-8, b) Mixing selexipag or crystalline polymorph thereof and a half of a disintegrant, and then adding another half of a disintegrant and mixing again, c) Adding % of a filler and mixing, then adding the remaining part of the filler and mixing again, d) Adding a half of else a filler and mixing, and then adding another half of the filler and mixing, e) Granulating the dry mixture at step (d) with the solution step (a) and obtained wet granules.
PCT/TR2023/050304 2022-04-05 2023-03-30 A film coated tablet comprising selexi̇pag and its preparation process WO2023195955A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2022005275 2022-04-05
TR2022/005275 2022-04-05

Publications (1)

Publication Number Publication Date
WO2023195955A1 true WO2023195955A1 (en) 2023-10-12

Family

ID=88243352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2023/050304 WO2023195955A1 (en) 2022-04-05 2023-03-30 A film coated tablet comprising selexi̇pag and its preparation process

Country Status (1)

Country Link
WO (1) WO2023195955A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017121806A1 (en) * 2016-01-15 2017-07-20 Sandoz Ag Pharmaceutical composition of selexipag
WO2018015975A1 (en) * 2016-07-22 2018-01-25 Sun Pharmaceutical Industries Limited Amorphous solid dispersion of selexipag
US20210069187A1 (en) * 2019-05-11 2021-03-11 RK Pharma Solutions LLC Stable pharmaceutical composition of Selexipag

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017121806A1 (en) * 2016-01-15 2017-07-20 Sandoz Ag Pharmaceutical composition of selexipag
WO2018015975A1 (en) * 2016-07-22 2018-01-25 Sun Pharmaceutical Industries Limited Amorphous solid dispersion of selexipag
US20210069187A1 (en) * 2019-05-11 2021-03-11 RK Pharma Solutions LLC Stable pharmaceutical composition of Selexipag

Similar Documents

Publication Publication Date Title
JP5625855B2 (en) Controlled release pharmaceutical composition
JP4999466B2 (en) Matrix-type sustained-release preparation containing basic drug or salt thereof and method for producing the same
JP5794650B2 (en) Solubility improving preparation for poorly soluble drugs
JP2013532651A (en) Pharmaceuticals for oral administration containing a mixture of silodosin and basic copolymer
US20140343076A1 (en) Pharmaceutical compositions of lurasidone
US11679105B1 (en) Pharmaceutical compositions of cabozantinib
EA031607B1 (en) Pharmaceutical composition
AU2017309302A1 (en) Solid pharmaceutical composition comprising amorphous sofosbuvir
EP3620156A1 (en) Composition having improved water solubility and bioavailability
WO2023195955A1 (en) A film coated tablet comprising selexi̇pag and its preparation process
WO2019004980A2 (en) Solid oral pharmaceutical compositions of dabigatran etexilate
WO2022153330A1 (en) Pharmaceutical compositions comprising acalabrutinib
WO2023195957A1 (en) A film coated tablet comprising selexi̇pag processed with wet granulation
WO2023195956A1 (en) A film coated tablet comprising selexi̇pag and at least one filler
US20110223245A1 (en) Controlled-release formulations of pramipexole
WO2023195953A1 (en) A film coated tablet comprising selexi̇pag
WO2023195954A1 (en) A film coated tablet comprising a solid dispersion of selexi̇pag
WO2017037645A1 (en) Stable pharmaceutical formulations of teriflunomide
WO2020122244A1 (en) Tablet and method for producing same
WO2018007556A1 (en) Pharmaceutical solid dispersion of a bcl-2 inhibitor, pharmaceutical compositions thereof, and uses for the treatment of cancer
RU2723255C2 (en) Extrudate with sodium mycophenolate to produce peroral solid dosage form
US20230119355A1 (en) Pharmaceutical compositions of a kinase inhibitor
WO2022162687A1 (en) Pharmaceutical compositions comprising nilotinib
AU2018293361B2 (en) Solid oral pharmaceutical compositions of dabigatran etexilate
WO2022029798A1 (en) Pharmaceutical compositions comprising ribociclib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23785126

Country of ref document: EP

Kind code of ref document: A1